Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

Bibliographic Details
Title: Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
Authors: Robidoux, André, Tang, Gong, Rastogi, Priya, Geyer, Charles E, Jr, Azar, Catherine A, Atkins, James N, Fehrenbacher, Louis, Bear, Harry D, Baez-Diaz, Louis, Sarwar, Shakir, Margolese, Richard G, Farrar, William B, Brufsky, Adam M, Shibata, Henry R, Bandos, Hanna, Paik, Soonmyung, Costantino, Joseph P, Swain, Sandra M, Mamounas, Eleftherios P, Wolmark, Norman
Source: In Lancet Oncology November 2013 14(12):1183-1192
Database: ScienceDirect
More Details
ISSN:14702045
DOI:10.1016/S1470-2045(13)70411-X
Published in:Lancet Oncology
Language:English